---
title: "Mind Medicine MindMed | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264730371.md"
datetime: "2025-11-06T22:06:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264730371.md)
  - [en](https://longbridge.com/en/news/264730371.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264730371.md)
---

# Mind Medicine MindMed | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.78, missing the estimate of USD -0.5.

EBIT: As of FY2025 Q3, the actual value is USD -46.66 M.

### Operational Metrics

-   **Net Loss**: For the three months ended September 30, 2025, the net loss was - $67.3 million, compared to - $13.7 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $133.4 million, compared to - $73.9 million for the same period in 2024.
-   **Total Operating Expenses**: For the three months ended September 30, 2025, total operating expenses were $45.7 million, compared to $24.8 million for the same period in 2024. For the nine months ended September 30, 2025, total operating expenses were $118.7 million, compared to $71.5 million for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $88.6 million, compared to - $53.8 million for the same period in 2024.
-   **Net Cash Used in Investing Activities**: For the nine months ended September 30, 2025, net cash used in investing activities was - $186.6 million.
-   **Net Cash Provided by Financing Activities**: For the nine months ended September 30, 2025, net cash provided by financing activities was $21.4 million, compared to $249.4 million for the same period in 2024.

### Unique Metrics

-   **Change in Fair Value of 2022 USD Financing Warrants**: For the three months ended September 30, 2025, the change in fair value was - $22.5 million, compared to $8.4 million for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to use the net proceeds from the October 2025 Offering to fund the research and development of its product candidates and for working capital and general corporate purposes. The company may also use a portion of the net proceeds to invest in or acquire additional businesses or compounds that are complementary to its own.
-   **Non-Core Business**: The company is exploring additional programs through external collaborations to expand its drug development pipeline and broaden the potential applications of its lead product candidates.

### Related Stocks

- [MNMD.US](https://longbridge.com/en/quote/MNMD.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [Will Strong Phase 3 Depression Data and Q2 Review Webcast Change Definium Therapeutics' (DFTX) Narrative](https://longbridge.com/en/news/294588855.md)
- [Is Definium Therapeutics (DFTX) Expensive As New GAD Study Sharpens Its Late Stage Case?](https://longbridge.com/en/news/293649367.md)
- [BUZZ-Definium Therapeutics jumps on depression drug trial data](https://longbridge.com/en/news/290467265.md)
- [Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment](https://longbridge.com/en/news/290445157.md)
- [Definium Therapeutics Sets $805 Million Public Offering at $34; Underwriting Agreement Signed](https://longbridge.com/en/news/290742592.md)